Abstract: Objective　To explore the clinical effect of Shugan Jieyu capsules combined with amisulpride in the treatment of schizophrenia of liver-spleen discordance. Methods　A total of 85 patients with schizophrenia of liver-spleen discordance confirmed in Sanmenxia Rehabilitation Hospital were enrolled between March 2019 and March 2021. They were simply randomly divided into an observation group and a control group, including 42 cases treated with amisulpride in the control group and 43 cases treated with Shugan Jieyu capsules and amisulpride in the observation group. All patients were continuously treated for 6 weeks. There were 23 males and 20 females in the observation group, with an age of (40.35±6.17) years old; there were 18 males and 24 females in the control group, with an age of (41.27±6.24) years old. The clinical curative effect in both groups was evaluated after treatment. The scores of traditional Chinese medicine (TCM) syndromes before and after treatment and the incidence of adverse reactions during treatment were compared between the two groups. Independent sample t test was used for inter-group comparison of the measurement data, paired t test was used for intra-group comparison of the measurement data, and χ² test was used for the count data. Results　The effective rate of the observation group was 95.35% (41/43), which was higher than that of the control group [80.95% (34/42)] (P<0.05). After 6 weeks of treatment, the scores of flank distension and pain, poor appetite, and fatigue and laziness in the observation group were (2.08±0.28) points, (1.96±0.37) points, and (2.17±0.21) points, respectively, which were lower than those in the control group [(2.23±0.22) points, (2.17±0.24) points, and (2.32±0.27) points] (all P<0.05). The incidence of adverse reactions was 13.95% (6/43) in the observation group and 9.52% (4/42) in the control group, without statistically significant difference (P>0.05). Conclusion　Shugan Jieyu capsules combined with amisulpride can significantly improve the clinical curative effect in patients with schizophrenia of liver-spleen discordance.

Key words: Shugan Jieyu capsules, Amisulpride, Liver-spleen discordance, Schizophrenia

摘要： 目的　探讨舒肝解郁胶囊联合氨磺必利治疗肝脾不和型精神分裂症的临床疗效。方法　选取2019年3月至2021年3月在三门峡市康复医院确诊的85例肝脾不和型精神分裂症患者，简单随机将其分为观察组和对照组。将采用氨磺必利治疗的42例患者纳入对照组，将采用舒肝解郁胶囊联合氨磺必利治疗的43例患者纳入观察组，均持续治疗6周。观察组男23例，女20例，年龄（40.35±6.17）岁；对照组男18例，女24例，年龄（41.27±6.24）岁。评估观察组和对照组患者治疗后的临床疗效，比较两组患者治疗前后的中医症候积分及治疗期间的不良反应发生率。计量资料组间比较采用独立样本t检验，组内治疗前后比较采用配对t检验，计数资料采用χ²检验。结果　观察组治疗有效率为95.35%（41/43），高于对照组80.95%（34/42）（P<0.05）。治疗6周后，观察组胁腹胀痛、食少纳呆及神疲懒言症候积分分别为（2.08±0.28）分、（1.96±0.37）分及（2.17±0.21）分，低于对照组的（2.23±0.22）分、（2.17±0.24）分及（2.32±0.27）分（均P<0.05）。观察组患者治疗期间不良反应发生率为13.95%（6/43）与对照组的9.52%（4/42）比较差异无统计学意义（P>0.05）。结论　舒肝解郁胶囊联合氨磺必利治疗可以明显提高肝脾不和型精神分裂症患者的临床疗效。

关键词: 舒肝解郁胶囊, 氨磺必利, 肝脾不和, 精神分裂症